FDA officials: Transforming evidence generation to tackle chronic diseases | RAPS
Leaders at the US Food and Drug Administration (FDA) are putting forward strategies to address the epidemic of chronic disease, with a focus on improving the quality of evidence generation for medical interventions through innovative trial design, use of reliable biomarkers, and leveraging artificial intelligence.